The Drug Controller General of India had last week approved Merck and Ridgeback’s antiviral molnupiravir for the treatment of mild-to-moderate Covid-19 at high risk of developing into severe disease.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3JEvlTR
0 Comments